Physician profile
Monica Lovins
NPI 1861732331
$17,821.61
in general payments reported to CMS, 2019-2025
39 companies · $7,098 in 2025
The $7,098 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,265 · 2022: $2,709 · 2023: $2,780 · 2024: $2,969 · 2025: $7,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,987 · Consulting Fee: $2,640 · Travel and Lodging: $1,041 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,986.74 |
| Consulting Fee | $2,640.00 |
| Travel and Lodging | $1,041.02 |
| Education | $179.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,566.50 | 2021-2025 | Livdelzi, Epclusa, Vemlidy |
| Abbvie INC. | $2,522.99 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,121.10 | 2021-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,080.89 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,053.88 | 2021-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $643.20 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $600.50 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $555.44 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $525.19 | 2021-2023 | |
| Madrigal Pharmaceuticals | $414.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $404.54 | 2022-2025 | Ibsrela |
| Amgen INC. | $321.66 | 2021-2023 | Avsola, Amjevita |
| Genzyme Corporation | $309.76 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $309.45 | 2021-2025 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $197.97 | 2022-2023 | Monoferric |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $169.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.99 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $145.55 | 2022-2024 | Dificid, Zinplava |
| Novo Nordisk INC | $140.76 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $138.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $138.22 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $135.71 | 2021-2023 | Linzess |
| Aimmune Therapeutics, INC. | $129.42 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $120.00 | 2025 | Uptravi, Opsumit |
| Endo Pharmaceuticals INC. | $119.67 | 2021 | |
| Medtronic, INC. | $107.81 | 2025 | Pillcam |
| Lilly USA, LLC | $107.21 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $104.14 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $85.42 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $75.50 | 2023 | Stelara, Tremfya |
| Organon LLC | $71.15 | 2021-2022 | |
| Braintree Laboratories, INC. | $68.70 | 2021-2023 | Sutab |
| Redhill Biopharma INC. | $52.03 | 2021 | |
| Intra-Sana Laboratories | $36.01 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Fresenius Kabi USA, LLC | $30.85 | 2023 | Idacio |
| Celltrion USA INC. | $19.99 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $19.73 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $17.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Lovins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.